<DOC>
	<DOCNO>NCT02678988</DOCNO>
	<brief_summary>The study consist eligibility screen period , two study period involve single dos tocilizumab ( TCZ ) accord open-label , randomize , two-period crossover design interval 6 week period , 6 week follow-up period . Healthy participant receive single subcutaneous ( SC ) injection TCZ via pre-filled syringe-needle safety device ( PFS-NSD ) single injection via autoinjector ( AI ) . The total duration study 16 week screen follow-up . After screen , eligible participant randomly assign one two possible treatment sequence ( Sequence 1 : AI-1000 G2 follow PFS-NSD Sequence 2 : PFS-NSD follow AI-1000 G2 ) assign one three injection site ( 1 : abdomen , 2 : thigh , 3 : upper arm ) . All participant group receive total two TCZ administration .</brief_summary>
	<brief_title>A Study Evaluate Bioequivalence Tocilizumab Following Subcutaneous Administration Via Autoinjector ( AI 1000-G2 ) Versus Pre-Filled Syringe Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Male participant partner childbearing potential must willing use two effective contraceptive method Female participant must either postmenopausal surgically sterile Intact normal skin area intend injection Body weight less ( &lt; ) 150 kilogram ( kg ) Have contraindication follow : detailed medical surgical history , complete physical examination , include vital sign , 12lead electro cardio gram ( ECG ) , hematology , blood chemistry , serology , urinalysis Participants know active current history recurrent Infectious disease Positive result hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus1 ( HIV1 ) HIV2 screen A history clinically significant gastrointestinal , renal , hepatic , cardiovascular , allergic disease Evidence malignant disease , malignancy diagnose within previous 5 year Use dependent within last 12 month substance abuse , include relevant past history alcohol abuse Participants history , currently active primary secondary immunodeficiency Participants smoke 10 cigarette per day equivalent tobacco Clinically relevant deviation normal physical examination , include vital sign Clinically relevant ECG abnormality screen Evidence atrial fibrillation , atrial flutter , right leave bundle branch block , WolfParkinsonWhite syndrome , cardiac pacemaker significant cardiac abnormality Known allergy TCZ ingredient subcutaneous ( SC ) formulation History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Known coagulopathy Clinically significant abnormality laboratory test result Immunization live attenuate vaccine prohibit within 4 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>